Proteins and Peptides

18 Sep 2021 Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting
15 Sep 2021 Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study
11 Sep 2021 Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline
10 Sep 2021 Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
09 Sep 2021 Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis
08 Sep 2021 AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan
04 Sep 2021 Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)
01 Sep 2021 Asher Bio Closes $108 Million Series B Financing
31 Aug 2021 Endevica Bio Reports TCMCB07 Preserves Lean Body Mass in Preclinical Cancer Cachexia Study
28 Aug 2021 Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting
28 Aug 2021 European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
26 Aug 2021 Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency
24 Aug 2021 HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic
24 Aug 2021 Stealth BioTherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome
24 Aug 2021 Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor
19 Aug 2021 AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)
19 Aug 2021 Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program
14 Aug 2021 Sesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs)
09 Aug 2021 Molecular Partners to Regain Global Rights to Abicipar
06 Aug 2021 FDA Approves New Treatment for Pompe Disease
05 Aug 2021 Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism
04 Aug 2021 Lumosa Therapeutics Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke
31 Jul 2021 Revolo Biotherapeutics Announces Clinical Trial Authorization to Initiate Phase 2 Trial of ‘1104 in Allergic Disease in the UK
30 Jul 2021 FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
29 Jul 2021 Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top